Sugi Predict

Sugi Predict / Compounds / SCHEMBL20456813

SCHEMBL20456813

SCHEMBL20456813

Cc1ccc(-c2cc(F)c(C=O)c(F)c2)nc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGS2 P35354 2/20 0.48
▸ CCR1 P32246 1/20 0.47
▸ CCR5 P51681 1/20 0.47
▸ CCR8 P51685 1/20 0.47
▸ HDAC6 Q9UBN7 1/20 0.47
▸ CYP3A4 P08684 1/20 0.46
▸ CYP2A6 P11509 1/20 0.46
▸ MET P08581 2/20 0.39
▸ NR1I2 O75469 2/20 0.39
▸ P2RX3 P56373 1/20 0.39
▸ P2RX2 Q9UBL9 1/20 0.39
▸ GRIA2 P42262 1/20 0.38
▸ ABL1 P00519 2/20 0.37
▸ PIK3CD O00329 1/20 0.37
▸ EGFR P00533 1/20 0.37
▸ HCK P08631 1/20 0.37
▸ SRC P12931 1/20 0.37
▸ KDR P35968 1/20 0.37
▸ PIK3CA P42336 1/20 0.37
▸ PIK3CB P42338 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20468884 0.83 GRM5 (0.40) NR1I2P2RX3P2RX2GRIA2ABL1
SCHEMBL20456681 0.78 PIK3CD (0.36) ABL1PIK3CDEGFRHCKSRC
SCHEMBL30205371 0.78 PIK3CD (0.36) ABL1PIK3CDEGFRHCKSRC
SCHEMBL13483666 0.76 CCR1 (0.71) PTGS2CCR1CCR5CCR8HDAC6
SCHEMBL19243068 0.76 CCR1 (0.54) PTGS2CCR1CCR5CCR8HDAC6
SCHEMBL13083660 0.75 PTGS2 (0.43) PTGS2CYP2A6ERN1
SCHEMBL14681239 0.75 CCR1 (0.48) PTGS2CCR1CCR5CCR8HDAC6
SCHEMBL24137558 0.75 CCR1 (0.52) PTGS2CCR1CCR5CCR8HDAC6
SCHEMBL14569988 0.75 CCR1 (0.52) PTGS2CCR1CCR5CCR8HDAC6
SCHEMBL16215329 0.74 GRM5 (0.49) PTGS2CCR1CCR5CCR8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260132139-A1 HIV INHIBITOR COMPOUNDS GILEAD SCIENCES INC (US) 2026-05-14 — — US disclosed
EP-4692076-A1 HIV INHIBITOR COMPOUNDS Gilead Sciences, Inc. (US) 2026-02-11 — — EP disclosed
US-12479853-B2 HIV inhibitor compounds GILEAD SCIENCES, INC. (US) 2025-11-25 — — US disclosed
EP-3909949-B1 ATAZANAVIR (ATV) ANALOGUES FOR TREATING HIV INFECTIONS GILEAD SCIENCES INC (US) 2025-10-15 — — EP disclosed
US-20250042910-A1 HIV INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. 2025-02-06 — — US disclosed
US-12084455-B2 HIV inhibitor compounds GILEAD SCIENCES, INC. (US) 2024-09-10 — — US disclosed
CN-115991708-A HIV inhibitor compounds 吉利德科学公司 2023-04-21 — — CN disclosed
US-20230027055-A1 HIV INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. 2023-01-26 — — US disclosed
US-20230027055-A1 HIV INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. 2023-01-26 — — US disclosed
CN-110536889-B HIV inhibitor compounds 吉利德科学公司 2022-12-16 — — CN disclosed
EP-3577110-B1 8-OXETAN-3-YL-3,8-DIAZABICYCLO[3.2.1]OCTAN-3-YL SUBSTITUTED COMPOUNDS AS HIV INHIBITORS GILEAD SCIENCES INC (US) 2021-04-21 — — EP disclosed
US-10752636-B2 HIV inhibitor compounds GILEAD SCIENCES, INC. (US) 2020-08-25 — — US disclosed
US-10752636-B2 HIV inhibitor compounds GILEAD SCIENCES, INC. (US) 2020-08-25 — — US disclosed
US-20190308983-A1 HIV INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. 2019-10-10 — — US disclosed
US-20190308983-A1 HIV INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. 2019-10-10 — — US disclosed
US-10294234-B2 HIV inhibitor compounds GILEAD SCIENCES, INC. (US) 2019-05-21 — — US disclosed
US-10294234-B2 HIV inhibitor compounds GILEAD SCIENCES, INC. (US) 2019-05-21 — — US disclosed
US-20180258097-A1 HIV INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. 2018-09-13 — — US disclosed
WO-2018145021-A1 ATAZANAVIR (ATV) ANALOGUES FOR TREATING HIV INFECTIONS GILEAD SCIENCES, INC. (US) 2018-08-09 — — WO disclosed
WO-2018145021-A1 ATAZANAVIR (ATV) ANALOGUES FOR TREATING HIV INFECTIONS GILEAD SCIENCES, INC. (US) 2018-08-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230027055-A1 HIV INHIBITOR COMPOUNDS NFATC1, SAMHD1, CCR5 PTGS2 3151/4885CCR1 180/4885CCR5 3/4885
US-20180258097-A1 HIV INHIBITOR COMPOUNDS NFATC1, SAMHD1, CCR5 PTGS2 3151/4885CCR1 180/4885CCR5 3/4885
US-10752636-B2 HIV inhibitor compounds NFATC1, SAMHD1, CCR5 PTGS2 3151/4885CCR1 180/4885CCR5 3/4885
US-12479853-B2 HIV inhibitor compounds NFATC1, SAMHD1, CCR5 PTGS2 3151/4885CCR1 180/4885CCR5 3/4885
US-20190308983-A1 HIV INHIBITOR COMPOUNDS HASPIN, NFATC1, NHERF1 PTGS2 3193/4885CCR1 400/4885CCR5 4/4885
US-12084455-B2 HIV inhibitor compounds NFATC1, SAMHD1, CCR5 PTGS2 3151/4885CCR1 180/4885CCR5 3/4885
US-20260132139-A1 HIV INHIBITOR COMPOUNDS SLC11A2, SLC6A15, NHERF1 PTGS2 3174/4885CCR1 2138/4885CCR5 93/4885
US-20250042910-A1 HIV INHIBITOR COMPOUNDS NFATC1, SAMHD1, CCR5 PTGS2 3151/4885CCR1 180/4885CCR5 3/4885
US-10294234-B2 HIV inhibitor compounds NFATC1, SAMHD1, CCR5 PTGS2 3151/4885CCR1 180/4885CCR5 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback